MDAT

MDAT
Clinical data
Routes of; administration	Oral
ATC code	none;
Legal status
Legal status	In general: uncontrolled;
Identifiers
	IUPAC name 5,6,7,8-tetrahydrobenzo[f][1,3]benzodioxol-6-amine;
CAS Number	101625-35-8 ; hydrochloride: 3446-21-8 ;
PubChem CID	36483;
ChemSpider	33531;
UNII	28IR5LC41Q; hydrochloride: BOX4U52EET ;
CompTox Dashboard (EPA)	DTXSID501017047 ;
Chemical and physical data
Formula	C11H13NO2
Molar mass	191.230 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C3Cc1cc2OCOc2cc1CC3N;

6,7-Methylenedioxy-2-aminotetralin (MDAT) is a drug developed in the 1990s by a team at Purdue University led by David E. Nichols.^[1] It appears to act as a serotonin releasing agent based on rodent drug discrimination assays comparing it to MDMA, in which it fully substitutes for, and additionally lacks any kind of serotonergic neurotoxicity.^[1] Hence, MDAT is considered likely to be a non-neurotoxic, putative entactogen in humans.

References

^ ^a ^b Nichols DE, Brewster WK, Johnson MP, Oberlender R, Riggs RM (February 1990). "Nonneurotoxic tetralin and indan analogues of 3,4-(methylenedioxy)amphetamine (MDA)". Journal of Medicinal Chemistry. 33 (2): 703–10. doi:10.1021/jm00164a037. PMID 1967651.

[pmid1967651-1] Nichols DE, Brewster WK, Johnson MP, Oberlender R, Riggs RM (February 1990). "Nonneurotoxic tetralin and indan analogues of 3,4-(methylenedioxy)amphetamine (MDA)". Journal of Medicinal Chemistry. 33 (2): 703–10. doi:10.1021/jm00164a037. PMID 1967651.

[1]

See also

References